Catheter Precision, Inc.
VTAKNYSEHealthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $819,000 | $420,000 | $442,000 | $14,000 | $22,000 | $259,000 |
| Operating income | −$21.1M | −$11.2M | −$78.1M | −$27.0M | −$29.3M | −$35.4M |
| Net income | −$17.2M | −$16.6M | −$70.6M | −$26.9M | −$25.1M | −$36.0M |
| Total assets | $15.9M | $27.8M | $30.7M | $16.8M | $21.0M | $33.4M |
| Total liabilities | $9.2M | $16.0M | $9.5M | $7.6M | $7.4M | $12.3M |
| Equity | $7.1M | $11.8M | $21.2M | $9.3M | $13.7M | $21.1M |
| EPS (diluted) | $-15.90 | $-126.91 | $-129.88 | $-25.98 | $-248.22 | — |
| Shares out. | 9.3M | 7.6M | 5.0M | 31.5M | 3.3M | 13.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −2581.6%
- Net margin
- −2098.0%
- Return on equity
- −243.6%
- Return on assets
- −108.3%
- Return on capital (ROCE)
- −176.9%
- Liabilities / assets
- 58.1%
- Debt / equity
- 1.31×
- Book value / share
- $0.76
- Revenue growth (YoY)
- 95.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -73.23distress
- Accruals / assets
- −56.0%clean
- Beneish M-Score
- -4.03normal
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 3 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 18, 2026
- NT 10-Qmissed a reporting deadline ↗Nov 15, 2023
- NT 10-Qmissed a reporting deadline ↗Aug 15, 2023
- NT 10-Qmissed a reporting deadline ↗May 16, 2023
- NT 10-Qmissed a reporting deadline ↗Nov 15, 2019
- NT 10-Qmissed a reporting deadline ↗Aug 15, 2019
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- C/M Capital Partners, LpPassive (13G)May 14, 2026
- Castaldo GregoryPassive (13G)Feb 11, 2026
- Reda JosephPassive (13G)Feb 11, 2026
- Armistice Capital, LlcPassive (13G)Aug 14, 2025
- Jenkins David AActivist (13D)Feb 3, 2025
- Jenkins Casey A.Activist (13D)Jan 3, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 18,181 | 1.0 | -51.4% |
| Apr 30, 2026 | 37,414 | 1.0 | -53.7% |
| Apr 15, 2026 | 80,782 | 1.0 | +92.0% |
| Mar 31, 2026 | 42,085 | 1.0 | -80.4% |
| Mar 13, 2026 | 214,479 | 1.0 | +184.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 18, 2026
- Unregistered equity sale · Modified shareholder rights · Amended charter or bylawsApr 23, 2026
- Shareholder voteApr 15, 2026
- Results of operationsMar 31, 2026
- Entered a material agreement · Unregistered equity sale · Modified shareholder rights · Amended charter or bylawsMar 9, 2026
- Entered a material agreement · Unregistered equity sale · Amended charter or bylaws · Regulation FD disclosureFeb 12, 2026
- Entered a material agreement · Unregistered equity sale · Modified shareholder rights · Amended charter or bylawsFeb 6, 2026
- Entered a material agreement · New financial obligationJan 8, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KFORM 8-KMay 18, 2026
- 10-QFORM 10-QMay 18, 2026
- NT 10-QFORM NT 10-QMay 18, 2026
- SCHEDULE 13G/AMay 14, 2026
- 10-K/AFORM 10-K/AApr 30, 2026
- 8-KFORM 8-KApr 23, 2026
- 8-KFORM 8-KApr 15, 2026
- 8-KFORM 8-KMar 31, 2026
- 10-KFORM 10-KMar 31, 2026
- 4FORM 4 - JENKINSMar 30, 2026
- 4FORM 4 - ANDERSONMar 30, 2026
- 4FORM 4 - ARNOMar 30, 2026
- 4FORM 4 - CARUSOMar 30, 2026
- 4FORM 4 COLOMBATTOMar 30, 2026
- DEFA14AFORM DEFA14AMar 23, 2026